loading page

Comparison of renal cell cancer surgery during Covid-19 pandemic with prepandemic period, Turkey multicenter study
  • +13
  • Abdullah Gurel,
  • Burhan Baylan,
  • Ibrahim Keles,
  • Ünal Öztekin,
  • Arif Demirbas,
  • Mustafa Karalar,
  • ata özen,
  • Kemal Ulusoy,
  • Mehmet Yilmaz,
  • Erol Ersekerci,
  • Burak Elmaagac,
  • Hasan Sulhan,
  • Ahmet Emin Dogan,
  • Mehmet Altan,
  • Murat Keske,
  • Mert Ali Karadag
Abdullah Gurel
Afyonkarahisar Health Sciences University

Corresponding Author:abdullahgurel@hotmail.com

Author Profile
Burhan Baylan
Afyonkarahisar Health Sciences University
Author Profile
Ibrahim Keles
Afyonkarahisar Health Sciences University
Author Profile
Ünal Öztekin
System Hospital
Author Profile
Arif Demirbas
Afyonkarahisar Health Sciences University
Author Profile
Mustafa Karalar
Afyonkarahisar Health Sciences University
Author Profile
ata özen
Eskişehir Osmangazi Üniversitesi Tıp Fakültesi
Author Profile
Kemal Ulusoy
Afyonkarahisar Health Sciences University
Author Profile
Mehmet Yilmaz
Istanbul Bagcilar Training and Research Hospital
Author Profile
Erol Ersekerci
Kirsehir Ahi Evran Universitesi
Author Profile
Burak Elmaagac
Eskişehir Yunus Emre Devlet Hastanesi
Author Profile
Hasan Sulhan
Adiyaman University
Author Profile
Ahmet Emin Dogan
Health Sciences University Diskapi Yildirım Beyazit Training and Research Hospital
Author Profile
Mehmet Altan
Author Profile
Murat Keske
Kayseri City Education and Research Hospital
Author Profile
Mert Ali Karadag
Kayseri City Education and Research Hospital
Author Profile

Abstract

Aim COVID-19 pandemic changed the priorities in medical field. Many elective surgeries for renal cell cancers (RCC) have been postponed. In this study, we aimed to examine the effects of the COVID-19 pandemic on the surgical treatment of RCC in Turkey. Methods 457 patients that underwent surgery for kidney tumor in the 2-year period between March 1, 2019 and February 28, 2021 in 9 centers in Turkey were analyzed retrospectively. Results The number of surgical treatments for RCC during the COVID-19 pandemic has decreased significantly compared to the same period before COVID-19. No significant differences were found between the two periods in terms of admission symptoms (p=0.32). However, while the rate of application due to hematuria was 6.1% in the pre-COVID-19 period, it was 13.1% during the COVID-19 period. Despite not being significant, this difference was still proportional. Two study periods differed significantly in terms of the rate of metastatic RCC detected in preoperative imaging (13.1% vs 6.1%, during COVID-19 and pre-COVID-19, respectively) (p=0.01). Moreover, the study periods differed significantly in terms of time between imaging and operation (55.98±51.02 vs 40.30±34.9 days, during COVID-19 and pre-COVID-19, respectively) (p=0.01). However, there was no significant difference between the two periods in terms of tumor size, type of surgery, and pathological stage (p>0.05). Conclusion There was a significant decrease in the number of RCC-related surgeries over 1-year period during the pandemic. However, the rate of surgery for metastatic disease increased. Covid-19 is a pandemic that continues to affect the whole world. Oncological diseases are negative affected in this process in terms of early diagnosis and treatment.